Welcome to our dedicated page for Veradigm SEC filings (Ticker: MDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veradigm Inc. SEC filings document the company’s healthcare technology business, OTC-traded common stock and formal disclosures around financial reporting, governance and capital structure. Recent filings include Current Reports on Form 8-K covering leadership appointments, preliminary financial information, material agreements and amendments to the company’s stockholder rights plan.
The filing record also includes late-filing notices for annual reports, disclosures about financial reporting and internal-control matters, board-observer and stockholder-agreement arrangements, and the conclusion of an SEC investigation without a recommended enforcement action. These filings record Veradigm’s public-company status, common stock trading symbol MDRX, rights-plan mechanics and governance changes while the company works through delayed periodic reporting.
Veradigm Inc. (MDRX) reports that a third-party vendor suffered a cybersecurity incident affecting data for a small number of Veradigm customers. An unauthorized party obtained vendor credentials to a Veradigm application programming interface and downloaded certain patients’ personal data, including some Social Security numbers, but no clinical or medical data.
The compromised credentials only allowed access through that limited interface and did not reach Veradigm’s broader network, servers, databases, or other systems, and there were no operational disruptions. Veradigm initiated its incident response protocols, notified law enforcement, and is notifying affected customers and individuals, offering credit monitoring where applicable. Potential liabilities are still being assessed, but Veradigm currently does not believe the incident is reasonably likely to have a material impact on its business, operations, financial condition, or results of operations.
Veradigm Inc. (MDRX) reported a scheduling change for its upcoming investor appearance at the 2026 Jefferies Healthcare Services and Technology Conference. The company’s fireside chat on September 15, 2026 in Nashville, Tennessee has been moved from 4:10 PM CT to 3:35 PM CT.
The change applies only to the Jefferies conference; previously announced details for Veradigm’s participation in the Deutsche Bank 2026 Healthcare Summit in New York, New York on September 16, 2026 remain the same. Veradigm stated that a live webcast of the Jefferies fireside chat will be available on its investor relations website.
Veradigm Inc. reported that its management team will participate in two investor conferences in September 2026, as a Regulation FD communication. At the 2026 Jefferies Healthcare Services and Technology Conference in Nashville on September 15, 2026, CEO Don Trigg and CFO Christian Greyenbuhl will hold one-on-one meetings and take part in a fireside chat at 4:10 PM CT, with a live webcast available on the company’s investor relations website. The same executives will also attend the Deutsche Bank 2026 Healthcare Summit in New York on September 16, 2026 for one-on-one meetings. Veradigm describes itself as a provider of clinical and revenue cycle solutions for independent practices, supporting over 20,000 provider practices with AI-focused data and technology.
Veradigm Inc. filed a Form 12b-25 stating it cannot file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 within the prescribed time without unreasonable effort and expense. The delay stems from extensive prior restatements and ongoing remediation of internal control failures that previously led the board to conclude that financial statements for 2020–2022 and multiple interim periods should no longer be relied upon.
The company filed a combined 2023 and 2024 Form 10-K on May 26, 2026, but still has not filed its 2025 Form 10-K and the 2025 and Q1 2026 Form 10-Qs, which it refers to collectively as Historical Late Filings. Veradigm also discloses that its common stock has been delisted from Nasdaq following noncompliance with listing rules and that it faces putative securities and derivative actions and commercial litigation related to its financial reporting and internal control issues. Management states it is working diligently to complete the delayed filings and the Q2 2026 Form 10-Q but gives no assurance on timing or future relisting.
Veradigm Inc. reported an update to its prior Stockholder Agreement with Charles Myers and Jessica Myers. The agreement, which provides Myers with observer rights on Veradigm’s board of directors, was previously amended in July 2025 and January 2026.
On June 25, 2026, Veradigm and the Myers Parties agreed to extend the term of this Agreement to December 31, 2026. Both sides indicated they do not anticipate any further extension beyond that date, signaling a defined end point for the current board observer arrangement.
Sacks Jonathan S reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. director and ten percent owner Jonathan S. Sacks reported an award of 42,507 Restricted Stock Units of common stock under the Veradigm Amended and Restated 2024 Stock Incentive Plan. The award was granted on June 1, 2026 and vests 100% on the first anniversary of the grant date.
Following this grant, Sacks holds 97,715 shares of Veradigm common stock directly. The filing also reports indirect holdings of 11,435,151 shares held by Stonehill Master Fund Ltd and 9,612,586 shares held by Stonehill Institutional Partners, L.P., entities managed by Stonehill Capital Management LLC, where Sacks is a managing member. He disclaims beneficial ownership of these securities except to the extent of any pecuniary interests.
STONEHILL CAPITAL MANAGEMENT LLC reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. reported an insider equity award connected to Stonehill-affiliated entities. On June 1, 2026, Jonathan Sacks received an award of 42,507 Restricted Stock Units of Veradigm common stock under the Amended and Restated 2024 Stock Incentive Plan, vesting 100% on the first anniversary of the grant date. Following this grant, Sacks is shown with 97,715 shares of common stock. Stonehill Master Fund Ltd. is reported with 11,435,151 Veradigm common shares and Stonehill Institutional Partners L.P. with 9,612,586 shares, while the reporting persons collectively disclaim beneficial ownership except for any pecuniary interests.
Veradigm Inc. director Bruce C. Felt Jr. received an equity award rather than trading shares in the market. He was granted 42,507 shares of common stock in the form of Restricted Stock Units under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan on June 1, 2026. The footnote explains that, on the first anniversary of the grant date, all of these Restricted Stock Units will automatically convert into an equal number of Deferred Stock Units under the Veradigm Inc. Director Deferred Compensation Plan, based on an election he has made. Those Deferred Stock Units will then be settled in shares of common stock on the tenth business day of January in the year following the year in which he ceases to be a director. After this grant, Felt directly holds 97,715 shares of Veradigm common stock according to the filing.
Zierhoffer Carol J reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. director Carol J. Zierhoffer received an equity award of 42,507 Restricted Stock Units on June 1, 2026. The award was granted under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan and will vest 100% on the first anniversary of the grant date.
After this grant, Zierhoffer directly holds 173,399 shares of Veradigm common stock. Because this is a compensation-related RSU award with no purchase price, it represents routine director equity compensation rather than an open-market share purchase or sale.
ASAR VINIT K reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. director Vinit K. Asar received an equity grant of 42,507 shares of Common Stock in the form of Restricted Stock Units on the Grant Date of June 1, 2026. The award was granted under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan and will vest 100% on the first anniversary of the Grant Date. Following this compensation-related grant, Asar directly holds 99,131 shares of Veradigm common stock in total, with no open-market purchase or sale reported in this filing.